Increased plasma exposures of five protoberberine alkaloids from coptidis rhizoma in streptozotocin-induced diabetic rats: Is PGP involved?

Planta Medica

Volumn 76, Issue 9, 2010, Pages 876-881

  Yu, Sen ^b   Yu, Yunli ^a   Liu, Li ^a   Wang, Xinting ^a   Lu, Shousi ^a   Liang, Yan ^a   Liu, Xiaodong ^a   Xie, Lin ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Simcere Pharmaceutical R and D Co Ltd   (China)

Author keywords

Coptis chinensis Franch; diabetes mellitus; Pglycoprotein; pharmacokinetics; protoberberine alkaloids; Ranunculaceae; rhodamine 123

Indexed keywords

BERBERINE; COPTIS RHIZOME EXTRACT; COPTISINE; EPIBERBERINE; GLYCOPROTEIN P; JATRORRHIZINE; PALMATINE; PROTOBERBERINE DERIVATIVE; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG PENETRATION; DUODENUM; ILEUM; INTESTINE PERFUSION; JEJUNUM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PORTAL VEIN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; AREA UNDER CURVE; BERBERINE ALKALOIDS; COPTIS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; P-GLYCOPROTEIN; PLANT EXTRACTS; PORTAL VEIN; RATS; RATS, SPRAGUE-DAWLEY; RHIZOME; RHODAMINE 123;

COPTIS CHINENSIS; RANUNCULACEAE; RATTUS;

EID: 77953836420     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1240815     Document Type: Article

References (39)

1. Tanaka T, Metori K, Mineo S, Hirotani M, Furuya T, Kobayashi S. Inhibitory effects of berberine-type alkaloids on elastase. Planta Med 1993 59 200-202
2. Shigeta K, Ootaki K, Tatemoto H, Nakanishi T, Inada A, Muto N. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a Coptidis Rhizoma extract and protoberberine alkaloids. Biosci Biotechnol Biochem 2002 66 2491-2494
3. Yokozawa T, Satoh A, Cho E J., Kashiwada Y, Ikeshiro Y. Protective role of Coptidis Rhizoma alkaloids against peroxynitrite-induced damage to renal tubular epithelial cells. J Pharm Pharmacol 2005 57 367-374
4. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang J D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004 10 1344-1351
5. Ko B S., Choi S B., Park S K., Jang J S., Kim Y E., Park S. Insulin sensitizing and insulinotropic action of berberine from Coptidis rhizome. Biol Pharm Bull 2005 28 1431-1437
6. Zhou H, Mineshita S. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther 2000 294 822-829
7. Bova S, Padrini R, Goldman W F., Berman D M., Cargnelli G. On the mechanism of vasodilating action of berberine: possible role of inositol lipid signaling system. J Pharmacol Exp Ther 1992 261 318-323
8. Iizuka N, Miyamoto K, Hazama S, Yoshino S, Yoshimura K, Okita K, Fukumoto T, Yamamoto S, Tangoku A, Oka M. Anticachectic effects of Coptidis rhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett 2000 158 35-41
9. Cui H S., Matsumoto K, Murakami Y, Hori H, Zhao Q, Obi R. Berberine exerts neuroprotective actions against in vitro ischemia-induced neuronal cell damage in organotypic hippocampal slice cultures: involvement of B-cell lymphoma 2 phosphorylation suppression. Biol Pharm Bull 2009 32 79-85
10. Yu S, Pang X Y., Deng Y X., Liu L, Liang Y, Liu X D., Xie L, Wang G J., Wang X T. A sensitive and specific liquid chromatography mass spectrometry method for simultaneous determination of berberine, palmatine, coptisine, epiberberine and jatrorrhizine from Coptidis Rhizoma in rat plasma. Int J Mass Spectrom 2007 268 30-37
11. Yu S, Yu Y L., Lu S S., Liu L, Liu X D. Pharmacokinetics of berberine, palmatine, coptisine, epiberberine and jatrorrhizine from Coptidis Rhizoma in diabetic rats. J China Pharm Univ 2008 39 526-529
12. Li L, Zhang Y. Changes of CYP2E1 activity in diabetic rat model. Yao Xue Xue Bao 1998 33 891-895
13. Kim Y C., Oh E Y., Kim S H., Lee M G. Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. Antimicrob Agents Chemother 2005 49 2528-2532
14. Kim Y C., Lee A K., Lee J H., Lee I, Lee D C., Kim S H., Kim S G., Lee M G. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 2005 26 114-123
15. Raza H, Ahmed I, Lakhani M S., Sharma A K., Pallot D, Montague W. Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenase and flutathione S-transferase in streptozotocin-induced diabetic rats. Biochem Pharmacol 1996 52 1639-1642
16. Pan G Y., Wang G J., Liu X D., Fawcett J P., Xie Y Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 2002 91 193-197
17. Liu H Y., Xu X, Yang Z H., Deng Y X., Liu X D., Xie L. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin- induced diabetic rats. Brain Res 2006 1123 245-252
18. Liu H Y., Liu X D., Jia L, Liu Y C., Yang H W., Wang G J., Xie L. Insulin therapy restores impaired function and expression of P-glycoprotein in blood-brain barrier of experimental diabetes. Biochem Pharmacol 2008 75 1649-1658
19. Tarui S, Yamada K, Hanafusa T. Animal models utilized in the research of diabetes mellitus-with special reference in insulin-associated diabetes. Prog Clin Biol Res 1997 229 211-223
20. Kamei J, Hirano S, Miyata S, Saitoh A, Onodera K. Effects of first-and second-generation histamine-H1-receptor antagonists on the pentobarbital-induced loss of the righting reflex in streptozotocin-induced diabetic mice. J Pharmacol Sci 2005 97 266-272
21. Steensma A, Faassen-Peters M A., Noteborn H P., Rietjens I M. Bioavailability of genistein and its glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. J Agric Food Chem 2006 54 8006-8012
22. Johnson B M., Chen W, Borchardt R T., Charman W N., Porter C J. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther 2003 305 151-158
23. Ando H, Nishio Y, Ito K, Nakao A, Wang L, Zhao Y L., Kitaichi K, Takagi K, Hasegawa T. Effect of endotoxin on P-glycoprotein mediated biliary and renal excretion of rhodamine 123 in rats. Antimicrob Agents Chemother 2001 45 3462-3467
24. Mouly S, Paine M F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003 20 1595-1599
25. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006 109 137-161
26. Chang Y L., Chou M H., Lin M F., Chen C F., Tsai T H. Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain. A microdialysis study. Life Sci 2001 69 191-199
27. Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. Inflamm Bowel Dis 2006 12 745-749
28. Yumoto R, Murakami T, Takano M. Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. Pharm Res 2003 20 765-771
29. Naud J, Michaud J, Boisvert C, Desbiens K, Leblond F A., Mitchell A, Jones C, Bonnardeaux A, Pichette V. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 2007 320 978-985
30. Liu H Y., Zhang D M., Xu X, Liu X D., Wang G J., Xie L. Attenuated function and expression of P-glycoprotein at bloodbrain barrier and increased brain distribution of phenobarbital in streptozotocin-induced diabetic mice. Eur J Pharmacol 2007 561 226-232
31. Tanaka S, Masuda M, Nakajima K, Ido N, Ohtsuka T, Nishida M, Utsumi H, Hirano T. P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration. Int Immunopharmacol 2009 9 284-290
32. Nishimura A, Honda N, Sugioka N, Takada K, Shibata N. Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures. Biol Pharm Bull 2008 31 2302-2308
33. Pires M M., Emmert D, Hrycyna C A., Chmielewski J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 2009 75 92-100
34. Barta C A., Sachs-Barrable K, Feng F, Wasan K M. Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers. Mol Pharm 2008 5 863-875
35. Turncliff R Z., Tian X, Brouwer K L. Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol 2006 71 1520-1529
36. Liu Y, Hao H, Xie H, Lv H, Liu C, Wang G J. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. Pharm Sci 2009 98 4391-4401
37. Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K, Kamijima M, Nakajima T, Miyamoto K, Wakusawa S, Hasegawa T. Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 2007 170 229-237
38. Lee D Y., Lee M G., Shin H S., Lee I. Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A. J Pharm Pharm Sci 2007 10 420-423
39. Bae S K., Kim J Y., Yang S H., Kim J W., Kim T, Lee M G. Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. Life Sci 2006 78 2287-2294